Ivantis gets $27M boost for trials of microstent in eye patients

02/4/2013 | Healio

A round of Series B financing led by Ascension Health Ventures has brought in $27 million for Ivantis. The company will use the money to conduct four global clinical studies of its Hydrus microstent, a tiny device that assists in restoring a glaucoma patient's natural eye outflow pathway.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR